TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3521254
Drug: Formulas I
Normalized name: Jarrow Formulas Inositol 750mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulas I and V providing 13 g protein and 350 kcal per day
Study: 30803326
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (room-temperature bag)
Study: 17617270
Drug: TMC125 (etravirine)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TMC125 (etravirine) 200 mg twice daily
Study: 11756100
Drug: Gadobutrol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadobutrol (1 mol/L) injected IV at doses of 0.1 or 0.3 mmol/kg
Study: 11756100
Drug: Gadobutrol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadobutrol (1 mol/L) injected IV
Study: 2660319
Drug: 4 capsules
Normalized name: Jynarque 60 MG / 30 MG Carton Pack, 4 Blister Cards, 14 Capsules Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules with 1 g concentrated fish oil preparation daily for 4 weeks (equivalent to 3.4 grams of EPA and DHA).
Study: 2660319
Drug: 4 capsules
Normalized name: Jynarque 60 MG / 30 MG Carton Pack, 4 Blister Cards, 14 Capsules Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules with 1 g concentrated fish oil preparation daily for 4 weeks (equivalent to 3.4 grams of EPA and DHA) in patients receiving OAC.
Study: 31136070
Drug: Zero dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zero dose of antibiotic prophylaxis (ABP)
Study: 31136070
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ABP (30 min before surgery)
Study: 31136070
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of ABP
Study: 28553988
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg intravenous acetaminophen
Study: 28553988
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg intravenous acetaminophen
Study: 23648697
Drug: Low-gluten diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-gluten diet (2 g gluten/d and 14 g whey protein/d)
Study: 23648697
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (16 g whey protein/d)
Study: 23648697
Drug: Gluten diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten diet (16 g/d)
Study: 23648697
Drug: Whey diet
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey diet (16 g/d)
Study: 8443029
Drug: Atenolol up
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol up to 100 mg
Study: 8443029
Drug: Atenolol up
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol up to 100 mg in combination with hydrochlorothiazide 25 mg
Study: 3097384
Drug: Glibenclamide +
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glibenclamide + Insulin infusion
Study: 26799345
Drug: Cyclosporine (CS)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CS) combined with topical agents
Study: 26799345
Drug: Cyclosporine (CS)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CS) monotherapy
Study: 24764674
Drug: Esomeprazole therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole therapy (20 mg esomeprazole, 400 mg clarithromycin, 750 mg amoxicillin for the first 7 days, all drugs given twice daily)
Study: 24764674
Drug: Lansoprazole therapy
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole therapy (30 mg lansoprazole, 400 mg clarithromycin, 750 mg amoxicillin for the first 7 days, all drugs given twice daily)
Study: 24764674
Drug: Esomeprazole therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole therapy
Study: 24764674
Drug: Lansoprazole therapy
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole therapy
Study: 22435741
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan (various dose sizes) without MAOI‐A
Study: 22435741
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan (various dose sizes) with MAOI‐A
Study: 22435741
Drug: Oral almotriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral almotriptan
Study: 16415708
Drug: Topiramate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (25 to 200 mg/d)
Study: 1801964
Drug: Danazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (200 mg)
Study: 1801964
Drug: Danazol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (400 mg)
Study: 6863583
Drug: experimenter-administered time-out
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: experimenter-administered time-out of fixed duration
Study: 6863583
Drug: experimenter-administered time-out
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: experimenter-administered time-out of duration determined by the subject
Study: 27862923
Drug: 50% reduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% reduction in TacER dose with targeted TacER trough level (C0) >3 μg/L (Group A)
Study: 27862923
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change in TacER dose (TacER C0 7-12 μg/L) (Group B)
Study: 25760561
Drug: Low-dose spiral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spiral computed tomography (LDCT) screening
Study: 2497135
Drug: GnRH-a treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-a treatment starting 8-10 days after ovulation (Group 2)
Study: 6983966
Drug: Carprofen 300
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carprofen 300 mg daily, b.i.d. administration
Study: 6983966
Drug: Carprofen 300
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carprofen 300 mg daily, t.i.d. administration
Study: 24733007
Drug: Active pharmacotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pharmacotherapy
Study: 21726301
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy (manual reading)
Study: 21726301
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy (semi-automated reading)
Study: 19841043
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin D supplements
Study: 14740153
Drug: D‐hormones (alphacalcidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐hormones (alphacalcidol and calcitriol)
Study: 3594460
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g oxiracetam
Study: 22816729
Drug: Linagliptin 2.5
Normalized name: linagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 2.5 mg twice daily
Study: 19710003
Drug: Ultra-low-dose end-expiratory
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose end-expiratory CT
Study: 15639696
Drug: DMPA 104
Normalized name: DMPA
DrugBank: Zytron (DB11768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA 104 mg/0.65 mL SC injection
Study: 7507135
Drug: Capsaicin cream
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cream 0.025%, 0.5% or 1.0% applied three times daily for 4 weeks
Study: 8349327
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg)
Study: 31310277
Drug: Intravenous Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Acetaminophen
Study: 23216584
Drug: Olmesartan/Amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan/Amlodipine combination (20 mg/5 mg)
Study: 19815148
Drug: Light buccally
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light buccally directed orthodontic force of 25 g
Study: 19216814
Drug: WHEY+CAS (casein
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHEY+CAS (casein and whey proteins mixture, 22 g protein, 836 kJ)
Study: 19216814
Drug: CAS (casein
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAS (casein only, 22 g protein, 836 kJ)
Study: 11902300
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron at 0.15 mg/kg
Study: 11902300
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron at 0.45 mg/kg
Study: 20519076
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CT)
Study: 16752024
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg bid after a 400 mg loading dose
Study: 16752024
Drug: Diclofenac SR
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac SR 75 mg bid
Study: 29021235
Drug: morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine + ibuprofen
Study: 22288725
Drug: Low-dose azithromycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose azithromycin
Study: 23291349
Drug: Low-dose azithromycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose azithromycin (in non-eosinophilic severe asthma)
Study: 3669078
Drug: Combination Treatment
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Treatment
Study: 11699827
Drug: Controlled-release tablets
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release tablets of diclofenac sodium with HPMC and NaCMC (1:2:1 ratio)
Study: 9872487
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol patches (50 microg daily) with intrauterine system releasing 20 microg of levonorgestrel daily
Study: 7520396
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment alone
Study: 7520396
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment with frequent ejaculation
Study: 3123302
Drug: Elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental diet therapy (administered nocturnally, at home, by continuous nasogastric infusion)
Study: 31994819
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical therapy (control group)
Study: 21732212
Drug: Daily self-weighing
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-weighing
Study: 30070045
Drug: Weekly weighing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly weighing
Study: 18806734
Drug: 23-valent vaccine
Normalized name: Pneumococcal 23-valent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent vaccine Pneumovax (0.5 mL administered intramuscularly)
Study: 16860190
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment until hemoglobin < 9 g/dL)
Study: 9375594
Drug: Pindolol 2.5
Normalized name: pindolol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 2.5 mg p.o. t.i.d. for 2 weeks
Study: 3033968
Drug: Halothane anaesthesia
Normalized name: Halothane
DrugBank: Halothane (DB01159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halothane anaesthesia with DA premedication (diazepam 0.25 mg kg‐1 and atropine 0.015 mg kg‐1)
Study: 3033968
Drug: DMS premedication
Normalized name: DMS
DrugBank: Succimer (DB00566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMS premedication (diazepam 0.5 mg kg‐1, morphine 0.15 mg kg‐1, scopolamine 0.01 mg kg‐1)
Study: 29609475
Drug: Control Condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Condition (CC) - registered emotions five times daily for four weeks
Study: 22762251
Drug: Astra Tech
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Astra Tech TiOblast implants
Study: 22762251
Drug: Brånemark turned
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark turned implants
Study: 18462354
Drug: Tosufloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tosufloxacin (300 mg twice daily for 2 days, initial dose 2 hours prior to biopsy)
Study: 1312588
Drug: Topotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan at 1.5 mg/m2
Study: 1312588
Drug: Topotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan at 2.0 mg/m2
Study: 1312588
Drug: Topotecan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (all doses)
Study: 6397365
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified semi-synthetic human insulin
Study: 7037511
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified porcine insulin
Study: 31203685
Drug: Proparacaine HCl
Normalized name: proparacaine HCl
DrugBank: Proparacaine (DB00807)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proparacaine HCl ophthalmic solution 0.5% plus breast milk
Study: 25388622
Drug: High-dose HAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose HAM flour cookie (33% wheat flour, 67% HAM flour)
Study: 23659987
Drug: Fesoterodine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine therapy
Study: 15690267
Drug: Peribulbar block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar block with propofol infusion
Study: 12567343
Drug: Intravenous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine 1 mg/kg
Study: 15690267
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 2 microg/kg
Study: 12826215
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2000 mg/d, CSA tapered to trough levels of 70 to 120 microg/L
Study: 10499601
Drug: Intradermal needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal needle injection of rV-CEA (10^7 or 10^8 pfu)
Study: 28253073
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with fixed appliance; administered monthly using a Diode laser (980 nm, 1 W, continuous wave, total energy density = 150 J/cm2)
Study: 25891006
Drug: Bendamustine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 60 mg/m2, thalidomide 100 mg, dexamethasone 20 mg
Study: 25891006
Drug: Bendamustine 100
Normalized name: bendamustine 100 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 100 mg/m2
Study: 23263772
Drug: LY2599506 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2599506 with dose titration
Study: 23263772
Drug: LY2599506 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2599506 with fixed dosing
Study: 23263772
Drug: LY2599506 (50-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2599506 (50-400 mg BID)
Study: 7688007
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group for elderly)
Study: 3726509
Drug: Budesonide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (2 X 800 micrograms daily)
Study: 17721099
Drug: HAART (Highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART (Highly Active Antiretroviral Therapy)
Study: 14713758
Drug: Chemoprevention agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoprevention agents
Study: 1858481
Drug: Intermittent diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent diazepam prophylaxis (few doses per year)
Study: 3109069
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 50 mg/day
Study: 6628518
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg/day
Study: 6628518
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 1000 mg/day
Study: 15818287
Drug: Gatifloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin (10 mg/kg of body weight once daily for 10 days)
Study: 23954024
Drug: Usual physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual physiotherapy treatment
Study: 19708635
Drug: C4‐5 facet
Approvals — FDA: no, EMA: no, PMDA: no
Description: C4‐5 facet joint injection
Study: 19708635
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (unilateral multifidi muscle injection)
Study: 11923699
Drug: C2 (2-hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: C2 (2-hr post-dose cyclosporine monitoring)
Study: 321992
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and flucloxacillin combination
Study: 9607385
Drug: Irbesartan 100
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan 100 mg
Study: 29545948
Drug: Trimethoprim (as
Normalized name: polymyxin B 10,000 UNT / trimethoprim (as trimethoprim sulfate) 0.1 % Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (as a weak CYP2C8 inhibitor)
Study: 23765178
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR 20 mg
Study: 22383336
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR 40 mg
Study: 22383336
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR 60 mg
Study: 24800725
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR (all doses)
Study: 18548292
Drug: Two-visit indirect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-visit indirect pulp treatment (IPT)
Study: 15708100
Drug: Three-times daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-times daily tobramycin
Study: 15708100
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tobramycin
Study: 15708100
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tobramycin (in children)
Study: 9502829
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg of pergolide
Study: 9502829
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of bromocriptine
Study: 7694914
Drug: Fluoxetine (N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (N = 6)
Study: 329825
Drug: Practolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (400 mg/day)
Study: 25849646
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg daily) with NaCl supplementation (100 mmol/24 h)
Study: 25849646
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg daily) with placebo
Study: 25166287
Drug: Comprehensive medication
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medication management services delivered postdischarge
Study: 9539899
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with oral conjugated oestrogens (0.625 mg daily) and cyclic medroxyprogesterone acetate (10 mg daily on Day 14‐27 of each menstrual cycle)
Study: 31705691
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) administration of tolfenamic acid (4 mg/kg body weight)
Study: 31705691
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of tolfenamic acid (4 mg/kg body weight)
Study: 20039972
Drug: Weekly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly follow-up (Control group)
Study: 18555912
Drug: Carbocisteine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocisteine (1500 mg per day for 1 year)
Study: 16162626
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C with L-arginine
Study: 16162626
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline with L-arginine
Study: 16162626
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C alone
Study: 10632230
Drug: Nondirective supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondirective supportive therapy
Study: 2209307
Drug: Computer algorithms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer algorithms for insulin dosage adjustment
Study: 2209307
Drug: Manual methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual methods for insulin dosage adjustment
Study: 2209307
Drug: Microprocessor device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microprocessor device for insulin dosage adjustment